Drug Trial Radar · NCT04641247
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
Last checked: Nov 20, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
37
Planned (sponsor's estimate)
Start
Apr 16, 2021
Primary completion
Dec 28, 2026
Study completion Dec 28, 2026
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Nov 23, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a global extension study to provide continued access to niraparib and further characterize the long-term safety of niraparib treatment in participants who are currently receiving treatment with niraparib within GlaxoSmithKline/TESARO-sponsored studies (NCT01847274, NCT02354586, NCT01905592, NCT03308942, NCT02657889) that has fulfilled the requirements for the primary objective.
Conditions
- Ovarian Neoplasms
- Breast Neoplasms
Interventions
NiraparibDrug
Niraparib tablets or capsules will be given once a day via the oral route.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs), serious adverse events (SAEs) and AEs of special interest (AESI)Time frame: Up to 5 years
- Number of participants with clinically significant changes in Eastern Co-operative Oncology Group (ECOG) performance statusTime frame: Up to 5 years
- Number of participants with clinically significant changes in hematology and clinical chemistry parametersTime frame: Up to 5 years
- Number of participants with clinically significant changes in vital signsTime frame: Up to 5 years
- Number of participants with clinically significant changes in physical examinationTime frame: Up to 5 years
- Number of participants with use of concomitant medicationsTime frame: Up to 5 years
Locations
25 sites in 8 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Tucson, Arizona · Completed
GSK Investigational Site
Encinitas, California · Recruiting
GSK Investigational Site
Los Angeles, California · Recruiting
GSK Investigational Site
Whittier, California · Completed
GSK Investigational Site
Jacksonville, Florida · Completed
GSK Investigational Site
Atlanta, Georgia · Recruiting
GSK Investigational Site
Harvey, Illinois · Recruiting
GSK Investigational Site
Boston, Massachusetts · Recruiting
GSK Investigational Site
Grand Rapids, Michigan · Recruiting
GSK Investigational Site
Morristown, New Jersey · Recruiting
GSK Investigational Site
Lake Success, New York · Recruiting
GSK Investigational Site
Charlotte, North Carolina · Recruiting
GSK Investigational Site
Cleveland, Ohio · Completed
GSK Investigational Site
Graz, Austria · Recruiting
GSK Investigational Site
Vienna, Austria · Recruiting
GSK Investigational Site
Kelowna, British Columbia, Canada · Recruiting
GSK Investigational Site
Toronto, Ontario, Canada · Recruiting
GSK Investigational Site
Montreal, Quebec, Canada · Recruiting
GSK Investigational Site
Odense C, Denmark · Completed
GSK Investigational Site
Nantes, France · Completed
GSK Investigational Site
Nice, France · Completed
GSK Investigational Site
Haifa, Israel · Recruiting
GSK Investigational Site
Cremona, Italy · Recruiting
GSK Investigational Site
Madrid, Spain · Recruiting
GSK Investigational Site
Madrid, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.